Literature DB >> 17191173

Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection.

Spencer D Polley1, Kevin K A Tetteh, Jennie M Lloyd, Onome J Akpogheneta, Brian M Greenwood, Kalifa A Bojang, David J Conway.   

Abstract

BACKGROUND: Plasmodium falciparum merozoite surface protein (MSP) 3 is an asexual blood-stage malaria vaccine candidate antigen. Sequence polymorphisms divide alleles into 2 major types, but the adaptive and immunological significance of the types has not been defined.
METHODS: One hundred one msp3 allele sequences were sampled from 2 populations living in areas where malaria is endemic and were analyzed for evidence of natural selection. Recombinant antigens representing full-length sequences of different allelic types and a relatively conserved C-terminal region were produced, to evaluate immunization-induced antibody responses in mice and protective associations for naturally acquired antibodies in a cohort of 319 Gambian children under surveillance for malaria.
RESULTS: Frequency-based statistical analyses indicated that polymorphisms are maintained by balancing selection in each of the 2 populations studied. Immunization of mice with full-length MSP3 antigens induced predominantly type-specific antibodies, and a large proportion of naturally acquired antibodies to MSP3 in humans also discriminated between the alleles. Among Gambian children, antibodies to allele-specific and conserved epitopes in MSP3 were associated prospectively with protection from clinical malaria, even after adjustment for age and for the presence of antibodies to other merozoite antigens.
CONCLUSIONS: A vaccine incorporating both major allelic types of this promising candidate antigen could be particularly useful for induction of protective immunity in infants and young children.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17191173     DOI: 10.1086/509806

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  79 in total

1.  Comparative Immunogenicities of full-length Plasmodium falciparum merozoite surface protein 3 and a 24-kilodalton N-terminal fragment.

Authors:  Maryam Imam; Yengkhom Sangeeta Devi; Akhilesh K Verma; Virander Singh Chauhan
Journal:  Clin Vaccine Immunol       Date:  2011-06-01

2.  Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria.

Authors:  Faith H A Osier; Gregory Fegan; Spencer D Polley; Linda Murungi; Federica Verra; Kevin K A Tetteh; Brett Lowe; Tabitha Mwangi; Peter C Bull; Alan W Thomas; David R Cavanagh; Jana S McBride; David E Lanar; Margaret J Mackinnon; David J Conway; Kevin Marsh
Journal:  Infect Immun       Date:  2008-03-03       Impact factor: 3.441

3.  Role of stochastic processes in maintaining discrete strain structure in antigenically diverse pathogen populations.

Authors:  Caroline O Buckee; Mario Recker; Eleanor R Watkins; Sunetra Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-29       Impact factor: 11.205

4.  Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure.

Authors:  Chiawei W Tsai; Peter F Duggan; Albert J Jin; Nicholas J Macdonald; Svetlana Kotova; Jacob Lebowitz; Darrell E Hurt; Richard L Shimp; Lynn Lambert; Louis H Miller; Carole A Long; Allan Saul; David L Narum
Journal:  Mol Biochem Parasitol       Date:  2008-11-27       Impact factor: 1.759

5.  Long- and short-term selective forces on malaria parasite genomes.

Authors:  Sanne Nygaard; Alexander Braunstein; Gareth Malsen; Stijn Van Dongen; Paul P Gardner; Anders Krogh; Thomas D Otto; Arnab Pain; Matthew Berriman; Jon McAuliffe; Emmanouil T Dermitzakis; Daniel C Jeffares
Journal:  PLoS Genet       Date:  2010-09-09       Impact factor: 5.917

Review 6.  What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity.

Authors:  Samson M Kinyanjui; Philip Bejon; Faith H Osier; Peter C Bull; Kevin Marsh
Journal:  Malar J       Date:  2009-10-28       Impact factor: 2.979

7.  Contrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum.

Authors:  Alyssa E Barry; Lee Schultz; Caroline O Buckee; John C Reeder
Journal:  PLoS One       Date:  2009-12-30       Impact factor: 3.240

8.  Heritability of antibody isotype and subclass responses to Plasmodium falciparum antigens.

Authors:  Nancy O Duah; Helen A Weiss; Annette Jepson; Kevin K A Tetteh; Hilton C Whittle; David J Conway
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

9.  Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months.

Authors:  John P A Lusingu; Samwel Gesase; Salum Msham; Filbert Francis; Martha Lemnge; Misago Seth; Samwel Sembuche; Acleus Rutta; Daniel Minja; Method D Segeja; Samuel Bosomprah; Simon Cousens; Ramadhani Noor; Roma Chilengi; Pierre Druilhe
Journal:  Malar J       Date:  2009-07-17       Impact factor: 2.979

Review 10.  The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis.

Authors:  Freya J I Fowkes; Jack S Richards; Julie A Simpson; James G Beeson
Journal:  PLoS Med       Date:  2010-01-19       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.